Anderson J, Harki D
RSC Med Chem. 2025; .
PMID: 39990163
PMC: 11843252.
DOI: 10.1039/d4md00963k.
Yasir M, Park J, Han E, Han J, Park W, Choe J
Biomolecules. 2025; 14(12.
PMID: 39766197
PMC: 11673129.
DOI: 10.3390/biom14121490.
Maqueda-Zelaya F, Valino-Rivas L, Milian A, Gutierrez S, Acena J, Garcia-Marin J
Arch Pharm (Weinheim). 2024; 358(1):e2400614.
PMID: 39604268
PMC: 11704032.
DOI: 10.1002/ardp.202400614.
Gonzalez-Alvarez H, Ensan D, Xin T, Wong J, Zepeda-Velazquez C, Cros J
J Med Chem. 2024; 67(6):4707-4725.
PMID: 38498998
PMC: 10983009.
DOI: 10.1021/acs.jmedchem.3c02308.
Bashore F, Marquez A, Chaikuad A, Howell S, Dunn A, Beltran A
Sci Rep. 2023; 13(1):6118.
PMID: 37059819
PMC: 10104807.
DOI: 10.1038/s41598-023-32854-4.
CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders.
Baier A, Szyszka R
Front Mol Biosci. 2022; 9:916063.
PMID: 36275622
PMC: 9582958.
DOI: 10.3389/fmolb.2022.916063.
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
Drewry D, Potjewyd F, Bayati A, Smith J, Dickmander R, Howell S
J Med Chem. 2022; 65(19):12860-12882.
PMID: 36111834
PMC: 9574855.
DOI: 10.1021/acs.jmedchem.2c00697.
The Therapeutic Potential of Targeting NIK in B Cell Malignancies.
Haselager M, Eldering E
Front Immunol. 2022; 13:930986.
PMID: 35911754
PMC: 9326486.
DOI: 10.3389/fimmu.2022.930986.
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
Lue J, OConnor O, Bertoni F
Ann Lymphoma. 2021; 4:7.
PMID: 34667996
PMC: 7611845.
DOI: 10.21037/aol-20-20.
Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.
Cheng J, Feng X, Li Z, Zhou F, Yang J, Zhao Y
RSC Med Chem. 2021; 12(4):552-565.
PMID: 34046627
PMC: 8128072.
DOI: 10.1039/d0md00361a.
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
Haselager M, Thijssen R, West C, Young L, van Kampen R, Willmore E
Cell Death Differ. 2021; 28(5):1658-1668.
PMID: 33495554
PMC: 8167103.
DOI: 10.1038/s41418-020-00692-w.
Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1).
Feng J, Lee P, Alaoui M, Barrett K, Castanedo G, Godemann R
ACS Med Chem Lett. 2019; 10(9):1260-1265.
PMID: 31531194
PMC: 6746091.
DOI: 10.1021/acsmedchemlett.8b00658.
Importance of Incorporating Protein Flexibility in Molecule Modeling: A Theoretical Study on Type I NIK Inhibitors.
Shen C, Liu H, Wang X, Lei T, Wang E, Xu L
Front Pharmacol. 2019; 10:345.
PMID: 31024312
PMC: 6465739.
DOI: 10.3389/fphar.2019.00345.
-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK.
Pippione A, Sainas S, Federico A, Lupino E, Piccinini M, Kubbutat M
Medchemcomm. 2018; 9(6):963-968.
PMID: 30108985
PMC: 6071728.
DOI: 10.1039/c8md00068a.
Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.
Begalli F, Bennett J, Capece D, Verzella D, DAndrea D, Tornatore L
Biomedicines. 2017; 5(3).
PMID: 28829404
PMC: 5618308.
DOI: 10.3390/biomedicines5030050.
Mitogen-Activated Protein Kinase 14 Promotes AKI.
Ortiz A, Husi H, Gonzalez-Lafuente L, Valino-Rivas L, Fresno M, Sanz A
J Am Soc Nephrol. 2016; 28(3):823-836.
PMID: 27620989
PMC: 5328147.
DOI: 10.1681/ASN.2015080898.
NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.
De Donatis G, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P
Oncogene. 2015; 35(21):2735-45.
PMID: 26364600
DOI: 10.1038/onc.2015.331.
Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?.
Noort A, Tak P, Tas S
Arthritis Res Ther. 2015; 17:15.
PMID: 25774937
PMC: 4308835.
DOI: 10.1186/s13075-015-0527-3.
NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis.
Noort A, van Zoest K, Weijers E, Koolwijk P, Maracle C, Novack D
J Pathol. 2014; 234(3):375-85.
PMID: 25043127
PMC: 4194146.
DOI: 10.1002/path.4403.
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.
Demchenko Y, Brents L, Li Z, Bergsagel L, McGee L, Kuehl M
Oncotarget. 2014; 5(12):4554-66.
PMID: 24980832
PMC: 4147345.
DOI: 10.18632/oncotarget.2128.